Objective: The purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine.Results: In this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migraine patients than when W-3 is administered alone.Trial Registration: This study was registered in Iranian Registry of Clinical Trials (IRCT) with ID number: NCT02532023.

Background: We tried to identify the interaction between dietary quality indices and apolipoprotein B Ins/Del and EcoR1 polymorphisms on cardio-metabolic risk factors in patients with type 2 diabetes mellitus (T2DM). Methods: This cross-sectional study recruited 700 adults with T2DM who visited diabetes referral centers in Tehran. The genotypes of Ins/Del and EcoR1 single nucleotide polymorphisms (SNP) were explored via polymerase chain reaction (PCR). Dietary quality index-international (DQI-I), healthy eating index-2015 (HEI-2015) and dietary phytochemical index (DPI) were calculated by semi-quantitative food frequency questionnaire (FFQ). Lipid, inflammatory, oxidative, hormonal and anthropometric variables were determined by standard methods. Results: We observed a significant interaction between DQI-I and Ins/Del SNP on leptin (P= 0.02 for crude model and P=0.01 for adjusted model (for age, physical activity, gender, smoking and alcohol intake) and 8-iso-prostaglandin F2 α (8-iso-PGF2α) (P=0.01 for both models), DPI and EcoR1 SNP on total cholesterol (TC) (P=0.03 for both models) and between Ins/Del SNP and HEI-2015 on interleukin-18 (IL-18) (P= 0.02 for crude model and P=0.03 for adjusted model). Furthermore, in crude but not in adjusted model there were close to meaningful interactions between EcoR1 SNP and DQI-I on total antioxidant capacity (TAC) (P=0.06) and between EcoR1 SNP and HEI-2015 on serum leptin (P=0.05) and superoxide dismutase (SOD) (p=0.05) levels. Conclusion: For the first time, our finding indicated that the association between DQI-I, HEI-2015 and DPI with IL-18, TC, leptin and 8-iso-PGF2α in patients with T2DM might be dependent on Ins/Del and EcoR1 variants in ApoB gene.

Objective The purpose of this clinical trial was to examine the effect of omega-3 fatty acids (W-3 FAs), nanocurcumin and their combination on serum levels and gene expression of VCAM in patients with episodic migraine. Results In this study, 80 patients were randomly divided in to 4 groups to receive for 2 months. Both serum levels and gene expression of VCAM showed remarkable decreases after single W-3 and after combined W-3 and nanocurcumin interventions. However, a borderline significant change and no remarkable change were observed after single nanocurcumin supplementation and in control group, respectively. While a significant difference between study groups in VCAM concentrations existed, there was no meaningful difference in VCAM gene expression among groups. It appears that the W-3 and combined W-3 and nanocurcumin can relieve VCAM serum level and its gene expression in patients with episodic migraine. Moreover, the combination of W-3 with nanocurcumin might cause more significant declines in VCAM level in the serum of migraine patients than when W-3 is administered alone.